Home | Welcome to Contract Pharma   
Last Updated Friday, May 22 2015


Financial Report: Lilly

Published July 24, 2013

2Q Revenues: $5.9 billion (+6%)

2Q Earnings: $1.2 billion (+31%)

YTD Revenues: $11.5 billion (+3%)

YTD Earnings: $2.8 billion (+42%)

Comments: Cymbalta sales increased 22% to $1.5 billion in the quarter. Cialis sales increased 13% to $529.4 million. Revenue in the U.S. increased 13% to $3.4 billion driven by increased prices, primarily for Cymbalta. Revenue outside the U.S. decreased 2% to $2.5 billion, impacted by foreign exchange rates, primarily the Japanese yen, and the loss of market exclusivity for Zyprexa (-25% to $283.2 million). Higher revenue and ongoing cost containment drove earnings growth.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On